Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2021-11-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment with glucocorticoids in COVID patients. Low-intervention, phase IV, open-label, randomised, low-intervention clinical trial comparing 2 active treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure

NCT04244591

COVID-19 Infections

COMPLETED PHASE2/PHASE3

Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19

NCT04343729

SARS-CoV Infection Severe Acute Respiratory Syndrome (SARS) Pneumonia

COMPLETED PHASE2

Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19

NCT04707534

Covid19

COMPLETED PHASE4

Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19

NCT04513184

Covid19

COMPLETED PHASE2

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780463

COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The use of high-dose bolus glucocorticoids in the treatment of patients with COVID-19 infection will increase the anti-inflammatory effect without increasing side effects. This will allow a better patient outcome, reducing the number of deaths and the need for intubation or admission to the Intensive Care Unit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corona Virus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Open-label, randomised clinical trial comparing 2 active treatments. Low-intervention clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RECOVERY

intermediate-dose dexamethasone (6mg/24h - 10 days)

Group Type ACTIVE_COMPARATOR

Dexamethasone

Intervention Type DRUG

6 mg/24h - 10 days

BOLUS

high-dose methylprednisolone bolus (250mg/4h - 3 days)

Group Type EXPERIMENTAL

Methylprednisolone

Intervention Type DRUG

250 mg/ 24h - 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

6 mg/24h - 10 days

Intervention Type DRUG

Methylprednisolone

250 mg/ 24h - 3 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Recovery Bolus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Over 18 years of age
2. Inpatient
3. Diagnosis of SARS-CoV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen
4. They present evidence in computerized axial tomography (CT) of pulmonary involvement attributed to the infection by COVID. Patients in whom CT scans are not performed must have suspected pulmonary involvement by clinical examination with simple compatible or suggestive radiology.
5. Requires supplementary oxygen due to basal saturation ≤ 93% (with ambient O2, 21%)

Exclusion Criteria

1. The patient's situation is so serious that the doctor in charge thinks he could die within 24 hours.
2. At the time of randomisation, patients require one of the following 4 ventilatory supports:

1. high-flow oxygen devices.
2. non-invasive mechanical ventilation.
3. invasive mechanical ventilation.
4. Extracorporeal membrane oxygenation (ECMO).
3. The patient is or has been treated in the 2 weeks prior to randomisation with glucocorticoids or inflammation modifying drugs, both conventional (thiopurines, cyclophosphamide, cyclosporine, tacrolimus), leflunomide, methotrexate, mycophenolate mofetil/mycophenolic acid, sulfasalazine, hydroxychloroquine or chloroquine) as synthetics or biologics directed against therapeutic targets (abatacept, belimumab, CD-20, IL1, IL6, Il12. 23, IL-23, Il.17, TNF, integrin α4β7 or Janus kinase inhibitors JAK). Patients who are only on maintenance treatment with doses of steroids less than or equal to 7.5 mg of prednisone or equivalent per day will not be excluded.
4. The patient is pregnant or breastfeeding.
5. The patient has a chronic renal disease is stage 4 or 5 (CCr \<30 ml/min).
6. Moderate to severe dementia at the investigator's discretion.
7. Hypersensitivity to any of the active ingredients or to any of the excipients included in its formulation.
8. Untreated systemic infections not caused by COVID-19.
9. Active stomach or duodenal ulcer.
10. Recent vaccination with live vaccines.
11. Other infection or disease that explains the lung disorder.
12. Inability of the patient to understand the study or to sign the informed consent unless consent is delegated to a legal representative.
13. Active participation in another clinical study in the last 15 days.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No